Also found in: Thesaurus, Medical, Wikipedia.


n. pl. throm·bol·y·ses (-sēz)
Dissolution or destruction of a thrombus.

throm′bo·lyt′ic (-bə-lĭt′ĭk) adj.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(Medicine) causing the break-up of a blood clot
(Pharmacology) a thrombolytic drug
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.thrombolytic - a kind of pharmaceutical that can break up clots blocking the flow of blood to the heart muscle
pharmaceutic, pharmaceutical - drug or medicine that is prepared or dispensed in pharmacies and used in medical treatment
Activase, tissue plasminogen activator - a thrombolytic agent (trade name Activase) that causes fibrinolysis at the site of a blood clot; used in treating acute myocardial infarction
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


a. trombolítico-a, rel. a un trombo o que causa la disolución de éste.
English-Spanish Medical Dictionary © Farlex 2012


adj & n trombolítico
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen.
Emergency department door-to-puncture time was compared for all IAT patients, IAT patients post-tissue-type plasminogen activator (tPA) treatment, and IAT patients post-tPA meeting thrombolytic adjudication criteria.
The current guidebook to ultra-early intravenous thrombolysis for cerebral infarction strict rules on the blood glucose of patients conforming to time windows because the over high blood sugar will increase the risk of intravenous thrombolysis and affect the prognosis.4,5 There are few studies about the effect of blood glucose fluctuation on thrombolytic therapy for cerebral infarction.
In this review, we will talk about thrombolytic therapy, which is the primary treatment for patients with especially life-threatening high-risk PTE and recent developments in this area.
Shock or persistent arterial hypotension, indicating overt RV failure at presentation, has long been identified as a key determinant of poor prognosis and represents the only widely accepted indication for (systemic) thrombolytic therapy to date.
Diffusion Pharmaceuticals announced receipt from the European Patent Office of a notice of intention to grant a patent related to the use of the company's compound trans sodium crocetinate, or TSC, in combination with the leading thrombolytic, tissue plasminogen activator, or tPA, in the treatment of ischemic stroke.
In particular, thrombolytic therapy is recommended in the high- and intermediate-risk groups, but there are different approaches to emergency treatment and long-term management.
Occlusive thrombus is then dealt with either by thrombolytic therapy (infusion of streptokinase), mechanical initiation of coronary artery blood flow by wiring followed by angioplasty(stenting) within 90 minutes of STEMI diagnosis (PPCI) or pharmaco-invasive therapy (PI) which involves thrombolysis (streptokinase) followed later on by percutaneous transluminal coronary angioplasty (PTCA)2.
Early clinical trials of intravenous thrombolytic therapy for AIS have primarily been designed to avoid increased symptomatic intracerebral hemorrhage (SICH), mortality rates, and negative treatment outcomes (5).
This unique combination could position TMS-007 as a best in class thrombolytic for individuals with acute ischemic stroke with potential for an extended treatment window as compared to current thrombolytic agents.
Patients who were treated with thrombolytic treatment had less seizures compared with patients who were not treated (p=0.043), and patients who were treated with thrombolytic treatment had higher mRS scores at admission (p=0.008) and lower mRS scores at discharge (p>0.001) (Table 2).